Nilvadipine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO HTN 4-16 mg/day; reduce to a max of 8 mg in patients w/ cirrhosis or on cimetidine. Cerebrovascular disorders 2-4 mg twice daily. Angina pectoris 8-16 mg/day.
Dosage Details
Oral
Cerebrovascular disorders
Adult: 2-4 mg bid

Oral
Angina pectoris
Adult: 8-16 mg/day

Oral
Hypertension
Adult: 4-16 mg/day; reduce dosage to a max of 8 mg in patients with cirrhosis or on cimetidine.
Contraindications
Cardiogenic shock, recent MI, unstable angina, severe renal impairment, CHF, aortic stenosis.
Adverse Reactions
Headache, peripheral oedema, dizziness, fatigue, flushing, paradoxical increase in ischaemic chest pain.
Drug Interactions
Increased hypotensive effects with other antihypertensive drugs such as β-blockers, some antipsychotics, ranitidine, and cimetidine.
Food Interaction
Increased bioavailability with grapefruit juice.
Action
Description: Nilvadipine is a dihydropyridine calcium-channel blocker. It is a peripheral and coronary vasodilator, but has little or no effect on cardiac conduction and negative inotropic activity is rarely seen at therapeutic doses. It results in vasodilatation leading to reduced peripheral resistance, BP, and afterload, increased coronary blood flow, and a reflex increase in heart rate. This results in an increase in myocardial oxygen supply and cardiac output.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Nilvadipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in